Not too bad, still plenty of cash and this quarter should see revenues increase significantly with more distribution channels kicking in.
Looks like they are lagging a bit with the Linnea deal. They need to move on that and get off their butts and finalise that arrangement so things can progress.
Would also like to see staff costs reduced if possible. Not good to have revenue decreasing and staff costs increasing. Some good announcements in the quarter so happy with the progress but they need to get this medicinal cannabis deal off the table and into action.
A bit of manipulation on close to try and get these pre ipo sellers out as low as possible. I say if they want to sell, make them sell out low and take it higher after.
Incredibly cheap imo at a $5m MC and $3m cash. So much room for growth. Dyor
BDA Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
